Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2023-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting agenda, director candidates, and financial summaries to inform shareholders' voting decisions. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2023-03-13 Korean
투자판단관련주요경영사항(코로나바이러스감염증-19 치료제 CP-COV03의 제2상 임상시험 탑라인 결과 발표 )
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details the top-line results of a Phase 2 clinical trial for a COVID-19 treatment. Since this is a formal regulatory announcement of material information regarding clinical trial outcomes, it falls under the 'Regulatory Filings' category as it does not fit into specific financial report types like 10-K or IR, and it is not merely an announcement of a report publication.
2023-03-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Hyundai Bioscience) regarding a significant change in revenue or profit structure (30% or more). This is a standard disclosure requirement in the Korean stock market (DART system) for listed companies to announce preliminary financial results before the final audit. Since it provides key financial highlights and reasons for the variance, it falls under the 'Earnings Release' category. FY 2022
2023-02-27 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a formal notice regarding the setting of a record date and the closure of the shareholder register for the purpose of determining voting rights for an upcoming Annual General Meeting. This type of regulatory disclosure is a standard corporate announcement required by stock exchanges and does not fit into specific categories like financial reports or proxy statements, making it a general regulatory filing.
2022-12-16 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Hyundai Bioscience Co., Ltd. for the period ending September 30, 2022. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which is characteristic of a formal quarterly financial filing. It is not an announcement of a report, but the report itself. 9M 2022
2022-11-14 Korean
[기재정정]주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Decision to Transfer Shares and Equity Securities of Another Corporation' (타법인 주식 및 출자증권 양도결정). It includes specific details such as the transfer date, transaction amount, counterparty information, and external evaluation results. Since this is a mandatory disclosure of a corporate transaction (divestiture) filed with a regulatory body, it falls under the 'Regulatory Filings' category.
2022-08-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.